We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Internal Tourniquet Provides Deep Wound Hemorrhage Control

By HospiMedica International staff writers
Posted on 25 Jan 2010
An innovative device that is inserted into a bullet wound and then inflated to apply pressure directly along the bullet's path helps control blood loss. More...


The TourniCath device is a balloon tamponade designed to control exsanguinating hemorrhage that is not manageable by conventional external means such as direct pressure, clotting agents, bandages, and tourniquets. The device works by internal wound track compression using a cylindrical, doubled walled, inflatable balloon. The balloon is made of two wall layers of material: the outer wall is nylon coated on the inside with polyurethane; the inner wall is a layer of soft polyurethane. The design makes the balloon resistant to punctures from sharp objects, like shrapnel, that might be inside the wound, and also helps the balloon to conform to the shape of the wound and compress it.

Designed for wounds that produce profuse hemorrhage due to a deep penetrating trauma in the groin, pelvis, shoulder, or axilla areas, the TourniCath has a smooth rounded tip and a smooth outer sheath covering the rolled balloon. Once inserted into the wound track--through either the entry or the exit wounds-and the outer sheath removed, the balloon is then inflated to a pressure sufficient to tamponade internal bleeding (usually 90 mmHg to 150 mmHg). The maximum potential inflation volume of the cylindrical balloon is 400 mL, and the dimensions at maximum volume are 20 cm in length and 5 cm in diameter. The TourniCath is under development by CardioCommand (Tampa, FL, USA), and is not indicated for abdominal or thoracic wounds. The Tournicath Device is not currently approved by the US. Food and Drug Administration (FDA) and is therefore not available for sale in the United States.

Related Links:

CardioCommand





Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Gas Consumption Analyzer
Anesthetic Gas Consumption Analyzer
Surgical Headlight
IsoTorch
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.